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as a loading dose (6-12 bg/kg/min for 10 minutes) then as a continu- 
ous infusion (0.075-0.2 bg/kg/min for 24 hours). One-way analysis of 
variance and the Wilcoxon test were employed. 
Results: Significant improvement in several hemodynamic parameters 
was observed; main results are in Table 1. Levosimendan was well toler- 
ated. At 30 days, 8 patients were event free; one patient was hospitalized; 
three patients received ventricular assist devices and heart transplanta- 
tions; and 6 patients died. 
Discussion: Our findings extend previous data on levosimendan to a 
population with severely compromised RV function. Augmentation in RV 
pressure generation indicates an increase in RV contractility rather than 
afterload reduction. Prospective studies with more patients are needed to 
support this. 
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Acute pulmonary embolism (PE) is followed by high mortality when in- 
creased fight ventricular (RV) afterload leads to RV dilatation and failure. 
Current pathophysiological concepts suggest that such RV failure is sec- 
ondary to an imbalance in RV oxygen supply/demand balance, leading to 
progressive RV ischemia and necrosis. However, this concept has never 
been proven in vivo yet. 
Anaesthetized farm pigs (n=18) were instrumented to measure RV peak 
pressure (RVpP), aortic flow (AF), RV end-diastolic segment length (RV 
SL) and segment-pressure loops (RV SPL), right coronary artery blood 
flow (RCA BF), and to withdraw RV venous blood to estimate RV oxy- 
gen consumption (RV MVO2). RVpP was increased by pulmonary artery 
banding (BG, n=9) that remained unchanged for 6 h. All parameters 
remained constant in controls (n=7). In BG at 6h, tachycardia and de- 
creased AF demonstrated overt heart failure, while serum troponin T 
was increased from 0,14-0,1 (baseline) to 0,64-0,2 mg/1. RV function in- 
creased at 10min but deteriorated at 3h and 6h, as indicated by decreased 
RVpP, RV SPL and RV dilatation (RV SL). In contrast, RCA-BF and 
RV MVO2 increased throughout the protocol in BG, excluding limited 
oxygen supply as causative for RV failure. Histology and electron mi- 
croscopy showed white cell infiltration and myocyte edema, but only 
single cell necrosis in BG. Pretreatment with dexamethasone (20 mg/kg, 
n=4) prevented white cell infiltration but did not preserve RV function. 
Table 1 
BG baseline 10rain 3h 6h 
HR (bpm) 94±6 101±6" 1 1 3 ± 5 " , #  113±7",# 
RVpP (mmHg) 27±2 64±3* 53± 1 " , #  49±1",# 
AF (l/rain) 6,8±0,5 5,2±0,4* 4,4±0,3*,# 4,1±0,3",# 
RV SL (ram) 14,2±0,6 15,0±0,7" 15,4±0,7",# 15,4±0,7",# 
RV SPL (mm*mmHg) 102±18  207±49* 109±25",# 79±19",# 
RCA BF (ml/min) 67±6 89±7* 92±6* 99±7*,# 
RV MVO2 (%) 100 1 5 2 ± 1 3 "  216±24",# 200±31",# 
mean±SEM, 2-way ANOVA, *:p<0,05 vs baseline, #:p<0,05 vs 10rain 
We conclude that progressive RV failure due to pressure load is not ex- 
plained by RV ischemia, RV necrosis or inflammatory cell infiltration. We 
speculate that pressure and stretch-induced signal transduction cascades 
rather than RV ischemia mediate RV failure during PE. 
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Greater Manchester, UK has one of the highest incidences of coronary 
artery disease and heart failure in Europe. Within the National Health 
Service, both cardiologists and general medical physicians are involved 
in the care of such patients. In November 2003 the National Institute of 
Clinical Excellence (NICE), UK, published guidance for clinicians on 
appropriate diagnosis and management of heart failure with the aim of 
standardising treatment. There is, however, no documented systematic 
analysis of current management of in-patients with heart failure within 
Greater Manchester. We therefore aimed to carry out an analysis of the 
care offered to patients admitted with heart failure within the acute med- 
ical hospitals in this region over a period of 6 months (lst June to 30th 
November 2003) immediately preceding the publication of the NICE 
guidelines. 
Methodology: all the 10 acute hospitals in Greater Manchester serving 
1.5 million people were invited to participate in the study. Using the 
patient administration system (PAS) database, we identified all admis- 
sions with suspected acute heart failure within each hospital. The medi- 
cal records of all the identified patients were then analysed to determine 
whether an echocardiographic confirmation of diagnosis was made and 
medication at discharge. 
Results: eight of the 10 acute hospitals in Greater Manchester opted to 
participate in the study. 699 admissions with suspected heart failure in the 
8 hospitals during the study period were identified. Twenty five patients 
were excluded (insufficient data), resulting in a final study sample of 
674 patients. Overall, 72% (483 patients) of the study population had an 
echocardiographic examination for confirmation of diagnosis but this var- 
ied between hospitals (range 57-83%). Speciality wise, 82% of patients 
under cardiology had an echocardiogram, compared with 67% under care 
of general medicine. Of the 483 patients with echocardiographic assess- 
ment, 73% (352 patients) were confirmed to have LV systolic dysfunction 
with 86% of these discharged on diuretics, 76% on an ACEI or AIIRA, 
32% on a beta-blocker, 31% on spironolactone, and 12% on digoxin (but 
52% of those in AF). 
Conclusions: the management and quality of care of heart failure within 
Greater Manchester in 2003 differed considerably between hospitals, 
with low rates of initiation of some therapies. It is plausible that some 
of these therapies may have been initiated after discharge. In view of the 
recommendations of the now published NICE guidelines on heart failure 
we plan another review of the service in 3 years. 
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EPHESUS demonstrated that patients with AMI complicated by heart 
failure (HF) and LVSD experienced significant reductions in all-cause 
mortality (ACM), cardiovascular mortality/CV hospitalization (CVM/H), 
CVM, and sudden cardiac death (SCD) with eplerenone (EPL) added to 
standard therapy. Because elevated heart rate (HR) increases risk in post- 
AMI patients with HF, the analysis of EPHESUS explores the impact of 
EPL on outcomes according to baseline HR. 
Patients with post-AMI HF and LVSD (EF _<40%) on standard therapies 
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were randomized 3-14 days after the index AMI to EPL (25 mg titrated to 
50 mg QD; n=3319) or placebo (PBO; n=3313). Patients were followed 
for up to 2.5 years (mean=16 months)• End point analyses were per- 
formed with a Cox proportional hazards regression model with treatment 
group as the only factor, stratified by geographic region• Treatment-by- 
HR (_<90/>90 bpm) factor interaction was based on the Wald's test of 
the interaction term in the Cox model• 
The rate of all-cause mortality in PBO-treated patients was 25.2% in 
those with baseline HR >90 bpm and 15.9% with baseline HR _<90 
bpm. Reductions in risk with EPL relative to PBO according to baseline 
HR are in Figure• Although most of the treatment-by-factor interaction 
P-values were not significant, the reduction in risk for SCD in patients 
with HR >90 bpm was greater compared to patients with HR <90 bpm 
(treatment-by-factor interaction P-value=0.04). 
Figure i. Relative Risk of End points by Baseline HR. 
At an average of 16 months of follow-up, EPL treatment demonstrated a 
consistent effect on the risk of ACM, CVM/H, and CVM in EPHESUS 
patients with baseline HR _<90 and >90 bpm. While EPL treatment 
reduced the risk of SCD in patients with HR _<90 and >90 bpm, patients 
with a baseline HR > 90 bpm may derive a larger treatment effect for this 
end point• 
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In EPHESUS, treatment with eplerenone (EPL) significantly reduced 
mortality and morbidity in patients with acute myocardial infarction 
(AMI) and LVSD with signs of heart failure (HF) when used with stan- 
dard therapies• Because post-AMI HF patients often receive statin ther- 
apy, this retrospective analysis evaluated the treatment effect of EPL used 
concurrently with standard HF treatment in EPHESUS patients w /and  
w/out concomitant statin therapy• 
Patients w/post-AMI HF and LVEF </= 40% on standard therapy were 
randomized 3-14 days after index AMI to EPL (25 mg titrated to 50 
mg QD; N=3319) or placebo (PBO; N=3313) and followed for up to 
2.5 years. The comparative analyses of treatment effects in patients who 
received statins from baseline (from index AMI up to 14 days post-AMI) 
and those who did not were performed using a Cox proportional hazards 
regression analysis stratified by the geographical region• Treatment-by- 
statin interaction was tested using Cox model• 
Patients not on statin therapy appeared to have increased risk for end 
points compared with those on statins; the rate of all-cause mortality in 
PBO-treated patients was 19.5% and not on statins and 13.6% in those 
on statin therapy• Risk reductions with EPL relative to PBO for patients 
w /and  w/out concomitant statin therapy were similar (P >/=0•12) for 
each endpoint (Figure 1). There was no evidence of toxicity related to the 
coadministration of EPL and statins, and the incidence of adverse events 
with EPL was similar to PBO. 
~ l ~ " ~ ' ^  "~:!i ~',~-':%'~ " ~  ":~ < "~  ~ 
. * ; , .  , ,  . , - >  , ; .  , ; , , >  
• + ,o. . - ,  
Figure L Relative Risk of Endpoints in EPHESUS by Baseline Statin Treatment. 
EPL treatment provided mortality and morbidity benefits in post-AMI HF 
patients w/and w/out concomitant statin therapy, with greater benefits in 
those receiving concomitant statin therapy• For each end point, event rates 
were lower with EPL than PBO, independent of statin treatment. 
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Introduction: heart failure (HF) is a frequent complication of acute 
coronary syndromes (ACS) and is associated with poor prognosis. Our 
goal was to find clinical parameters on admission that could predict HF, 
thereby helping select the most suitable management strategy. 
Methods: we studied 1045 patients (61.44-12.5 years-old, 71.7% males) 
consecutively admitted in our cardiology department with ACS. Clinical 
and laboratory parameters were obtained during the first 48 hours. The 
outcome was development of clinical signs of HF during hospitalisation. 
Results: cardiovascular risk factors were found in a significant propor- 
tion of our sample (hypertension in 55.9%, diabetes mellitus in 29.1%, 
current or previous smoking in 50%, dyslipidaemia in 62.2%, body mass 
index > 30 Kg/m 2 in 20%). Forty-three percent of the patients had ACS 
with ST segment elevation (STEMI) and 40% had left ventricular systolic 
dysfunction (LVSD). Multivessel and/or left main coronary artery disease 
were found in 52.3%. Revascularisation was performed in 60.7%. Heart 
failure occurred in 15.9%. Variables associated with development of HF 
in univariate analysis were: male sex (OR 0.446, 95%CI 0.317-0.629), 
age (OR 1.061, 95%CI 1.045-1.068), smoking (OR 0.463, 95%CI 0.328- 
0.655), hypertension (OR 1.528, 95%CI 1.083-2.157), diabetes (OR 
2.639, 95%CI 1.878-3.709), dyslipidaemia (OR 0.531, 95%CI 0.380- 
0.742), LVSD (OR 8.042, 95%CI 5.378-12.025), STEMI (OR 2.130, 
95%CI 1.519-2.987), revascularisation (OR 0.513, 95%CI 0.358-0.736), 
serum creatinine (OR 1.173, 95%CI 1.044-1.318), hematocrit (OR 0.9, 
95%CI 0.871-0.929), glycaemia (OR 1.07, 95%CI 1.05-1.091) and tro- 
ponin I (OR 1.004, 95%CI 1.002-1.006). Multivariate analysis, using a 
stepwise binary logistic regression method, revealed that the only ones 
with independent predictive value were: age (OR 1.056, 95%CI 1.036- 
1.076), LVSD (OR 6.381, 95%CI 4.009-10.156), STEMI (OR 1.628, 
95%CI 1.056-2.510), hematocrit (OR 0.916, 95%CI 0.882-0.952) and 
glycaemia (OR 1.064, 95%CI 1.039-1.090, for each 10 mg/dl increment). 
Using the predicted probabilities of this model we constructed a ROC 
curve. Its AUC was 0.85 (p < 0.001 vs ND). Using the best cut-off of pre- 
dicted probabilities this model showed a sensitivity of 88.3%, specificity 
of 64.5%, positive predictive value of 33% and negative predictive value 
of 96.7%. 
Conclusion: in-hospital post-ACS heart failure might be predicted on 
admission using common practice clinical and laboratory data. 
